You are here: Welcome to the MPKB » Welcome to the MPKB » Diseases » Hypertension (high blood pressure)
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:diseases:hypertension [01.04.2019] – [Notes and comments] sallieqhome:diseases:hypertension [01.04.2019] – [Notes and comments] sallieq
Line 123: Line 123:
 //BROKEN LINK// [[http://hyper.ahajournals.org/cgi/content/full/44/3/253|Is Vascular Endothelial Growth Factor a Missing Link Between Hypertension and Inflammation?]] //BROKEN LINK// [[http://hyper.ahajournals.org/cgi/content/full/44/3/253|Is Vascular Endothelial Growth Factor a Missing Link Between Hypertension and Inflammation?]]
  
-ANOR DEAD LINK +ANOR //DEAD LINK// 
 [[http://hyper.ahajournals.org/content/hypertensionaha/early/2014/07/07/HYPERTENSIONAHA.114.03282.full.pdf|Dose-Dependent  Arterial  Destiffening  and  Inward   [[http://hyper.ahajournals.org/content/hypertensionaha/early/2014/07/07/HYPERTENSIONAHA.114.03282.full.pdf|Dose-Dependent  Arterial  Destiffening  and  Inward  
 Remodeling  After  Olmesartan  in  Hypertensives  With   Remodeling  After  Olmesartan  in  Hypertensives  With  
 Metabolic  Syndrome]] Metabolic  Syndrome]]
  
-link to current research by 2 authoers [[http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Savoia%20C%22[Author]|Savoia C]], [[http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Schiffrin%20EL%22[Author]|Schiffrin EL.]]+link to current research by 2 authers [[http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Savoia%20C%22[Author]|Savoia C]], [[http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Schiffrin%20EL%22[Author]|Schiffrin EL.]]
  
 Vitamins  Vitamins 
Line 169: Line 169:
 <blockquote>Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women. (({{pubmed>long:21061834}})) <blockquote>Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women. (({{pubmed>long:21061834}}))
  
-http://www.ncbi.nlm.nih.gov/pubmed/21061834+http://www.ncbi.nlm.nih.gov/pubmed/21061834 (USED on page --- //Sallie Q 01.04.2019// )
  
 CONCLUSION: The administration of olmesartan improved blood pressure, insulin, HOMA, visfatin and lipid profile in hypertensive obese women. Irbesartan improved blood pressure and lipid levels. CONCLUSION: The administration of olmesartan improved blood pressure, insulin, HOMA, visfatin and lipid profile in hypertensive obese women. Irbesartan improved blood pressure and lipid levels.
Line 182: Line 182:
  
 ~~~~ ~~~~
 +(part below ref. USED on page ---  --- //Sallie Q 01.04.2019// )
 Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. (({{pubmed>long:21063874}})) Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. (({{pubmed>long:21063874}}))
  
Line 233: Line 233:
  
 PMID: PMID:
-21504378</blockquote> +21504378 (part  USED on page --- //Sallie Q 01.04.2019//</blockquote> 
home/diseases/hypertension.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.